Allergic rhinitis is seasonal or perennial itching, sneezing, rhinorrhea, nasal congestion, and sometimes conjunctivitis, caused by exposure to pollens or other allergens. Diagnosis is by history and occasionally skin testing. First-line treatment is with a nasal corticosteroid (with or without an oral or a nasal antihistamine) or with an oral antihistamine plus an oral decongestant.

Allergic rhinitis may occur seasonally or throughout the year (as a form of perennial rhinitis). Seasonal rhinitis is usually allergic. At least 25% of perennial rhinitis is nonallergic.

Seasonal allergic rhinitis (hay fever) is most often caused by plant allergens, which vary by season. Common plant allergens include

• Spring: Tree pollens (eg, oak, elm, maple, alder, birch, juniper, olive)
• Summer: Grass pollens (eg, Bermuda, timothy, sweet vernal, orchard, Johnson) and weed pollens (eg, Russian thistle, English plantain)
• Fall: Other weed pollens (eg, ragweed)

Causes also differ by region, and seasonal allergic rhinitis is occasionally caused by airborne fungal spores.

Perennial rhinitis is caused by year-round exposure to indoor inhaled allergens (eg, dust mites, cockroaches, animal dander) or by strong reactivity to plant pollens in sequential seasons.

Allergic rhinitis and asthma frequently coexist; whether rhinitis and asthma result from the same allergic process (one-airway hypothesis) or rhinitis is a discrete asthma trigger is unclear.

The numerous nonallergic forms of perennial rhinitis include infectious, vasomotor, drug-induced (eg, aspirinSome Trade Names
BUFFERIN
ECOTRIN
GENACOTE
Click for Drug Monograph
- or NSAID-induced), and atrophic rhinitis (see Nose and Paranasal Sinus Disorders: Rhinitis).

Symptoms and Signs

Patients have itching (in the nose, eyes, or mouth), sneezing, rhinorrhea, and nasal and sinus obstruction. Sinus obstruction may cause frontal headaches; sinusitis is a frequent complication. Coughing and wheezing may also occur, especially if asthma is also present.

The most prominent feature of perennial rhinitis is chronic nasal obstruction, which, in children, can lead to chronic otitis media; symptoms vary in severity throughout the year. Itching is less prominent than in seasonal rhinitis.

Signs include edematous, bluish-red nasal turbinates, and, in some cases of seasonal allergic rhinitis, conjunctival injection and eyelid edema.

Diagnosis

• Clinical evaluation
• Occasionally skin testing, radioallergosorbent testing (RAST), or both

Allergic rhinitis can almost always be diagnosed based on history alone. Diagnostic testing is not routinely needed unless patients do not improve when treated empirically; for such patients, skin tests (Allergic, Autoimmune, and Other Hypersensitivity Disorders: Specific tests) are done to identify a reaction to pollens (seasonal) or to dust mite, cockroach, animal dander, mold, or other antigens (perennial), which can be used to guide additional treatment. Occasionally, skin test results are equivocal, or testing cannot be done (eg, because patients are taking drugs that interfere with results); then, RAST (see Allergic, Autoimmune, and Other Hypersensitivity Disorders: Specific tests) is done. Eosinophilia detected on nasal smear plus negative skin tests suggests aspirinSome Trade Names
BUFFERIN
ECOTRIN
GENACOTE
Click for Drug Monograph
sensitivity or nonallergic rhinitis with eosinophilia (NARES).

Diagnosis of nonallergic perennial rhinitis is usually also based on history. Lack of a clinical response to treatment for assumed allergic rhinitis and negative results on skin tests and/or RAST also suggest a nonallergic cause.

Treatment

• Antihistamines, decongestants, nasal corticosteroids, or a combination
• For perennial rhinitis, removal or avoidance of allergens
• For seasonal rhinitis, sometimes immunotherapy
• For severe, refractory rhinitis, desensitization

Treatment of seasonal and perennial allergic rhinitis is generally the same, although attempts at environmental control (eg, eliminating dust mites and cockroaches—see Allergic, Autoimmune, and Other Hypersensitivity Disorders: Prevention) are recommended for perennial rhinitis.

The most effective first-line drug treatments are

• Nasal corticosteroids with or without oral or nasal antihistamines (see Allergic, Autoimmune, and Other Hypersensitivity Disorders: Inhaled Nasal Corticosteroids and Mast Cell Stabilizers)
• Oral antihistamines plus oral decongestants

Less effective alternatives include nasal mast cell stabilizers (eg, cromolynSome Trade Names
CROLOM
INTAL
NASALCROM
Click for Drug Monograph
) given bid to qid, the nasal H₁ blocker azelastineSome Trade Names
ASTELIN
OPTIVAR
Click for Drug Monograph
2 puffs once/day, and nasal ipratropiumSome Trade Names
ATROVENT
Click for Drug Monograph
0.03% 2 puffs q 4 to 6 h, which relieves rhinorrhea. Nasal drugs are often preferred to oral drugs because less of the drug is absorbed systemically.

Table 3
PrintOpen table in new window
Inhaled Nasal Corticosteroids and Mast Cell Stabilizers Drug Dose per Spray Initial Dose (Sprays per Nostril) Sprays or Actuations per Canister Inhaled nasal corticosteroids BeclomethasoneSome Trade Names BECLOVENT BECONASE Click for Drug Monograph 42 μg 6–12 yr: 1 spray bid > 12 yr: 1 spray bid to qid 200 BudesonideSome Trade Names PULMICORT RHINOCORT Click for Drug Monograph 32 μg ≥ 6 yr: 1 spray once/day 200 FlunisolideSome Trade Names NASALIDE Click for Drug Monograph 29 μg 6–14 yr: 1 spray tid or 2 sprays bid Adults: 2 sprays bid 125 FluticasoneSome Trade Names CUTIVATE FLONASE FLOVENT Click for Drug Monograph 50 μg 4–12 yr: 1 spray once/day > 12 yr: 2 sprays once/day 120 TriamcinoloneSome Trade Names ARISTOCORT KENACORT KENALOG NASACORT Click for Drug Monograph 55 μg > 6–12 yr: 1 spray once/day > 12 yr: 2 sprays once/day 100 Mast cell stabilizers AzelastineSome Trade Names ASTELIN OPTIVAR Click for Drug Monograph 137 μg 5–11 yr: 1 spray bid > 12 yr: 1–2 sprays bid 200 CromolynSome Trade Names CROLOM INTAL NASALCROM Click for Drug Monograph 5.2 mg ≥ 6 yr: 1 spray tid or qid 200

Intranasal saline, often forgotten, helps mobilize thick nasal secretions and hydrate nasal mucous membranes; various saline solution kits and irrigation devices (eg, squeeze bottles, bulb syringes) are available OTC, or patients can make their own solutions.

Desensitization immunotherapy may be more effective for seasonal than for perennial allergic rhinitis; it is indicated when

• Symptoms are severe.
• Allergen cannot be avoided.
• Drug treatment is inadequate.

First attempts at desensitization should begin soon after the pollen season ends to prepare for the next season; adverse reactions increase when desensitization is started during the pollen season because the person's allergic immunity is already maximally stimulated.

MontelukastSome Trade Names
SINGULAIR
Click for Drug Monograph
, a leukotriene blocker, relieves allergic rhinitis symptoms, but its role relative to other treatments is uncertain. OmalizumabSome Trade Names
XOLAIR
Click for Drug Monograph
, an anti-IgE antibody, is under study for treatment of allergic rhinitis but will probably have a limited role because less expensive, effective alternatives are available.

Treatment of NARES is nasal corticosteroids. Treatment of aspirinSome Trade Names
BUFFERIN
ECOTRIN
GENACOTE
Click for Drug Monograph
sensitivity is avoidance of aspirinSome Trade Names
BUFFERIN
ECOTRIN
GENACOTE
Click for Drug Monograph
and nonselective NSAIDs (which can cross-react with aspirinSome Trade Names
BUFFERIN
ECOTRIN
GENACOTE
Click for Drug Monograph
), plus desensitization and leukotriene blockers as needed.

Key Points

• Seasonal rhinitis is usually an allergic reaction to pollens.
• Patients may have cough, wheezing, frontal headache, sinusitis, or, particularly in children with perennial rhinitis, otitis media.
• Diagnosis is usually based on the history; skin tests and sometimes RAST are needed only when patients do not respond to empiric treatment.
• Try nasal corticosteroids first because they are the most effective treatment and have few systemic effects.

Last full review/revision July 2012 by Peter J. Delves, PhD

Content last modified July 2012